Favorable five-year survival reported for patients with advanced cancer treated with the immunotherapy
(Johns Hopkins Medicine) A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the immunotherapy drug nivolumab (anti-PD-1) as a treatment for patients whose previous therapies failed to stem their advanced melanoma, renal cell carcinoma (RCC) or non-small-cell lung cancer (NSCLC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2019 Category: International Medicine & Public Health Source Type: news
Targeted Therapy Proves Its Worth in Metastatic Kidney Cancer Patients
A new study looked at targeted vs nontargeted therapy in real world patients with renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Nivolumab Trial Failure Raises the Question of Brain Imaging in Kidney Cancer
Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results. (Source: CancerNetwork)
Source: CancerNetwork - July 8, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Pembrolizumab/axitinib too costly in advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2019 Category: Drugs & Pharmacology Source Type: news
Targeted Therapies Linked to Survival Benefits for Older Patients With Advanced Renal Cancer Targeted Therapies Linked to Survival Benefits for Older Patients With Advanced Renal Cancer
Targeted therapies were associated with"modest survival advantages" in elderly Medicare patients with metastatic renal cell carcinoma (mRCC) in a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Study Reveals Lower Predictive Ability for Renal Cancer Models
FRIDAY, June 21, 2019 -- Prospective validation of existing renal cell carcinoma (RCC) prediction models demonstrates a decrease in their predictive ability, according to a study published online June 19 in the Journal of Clinical Oncology.
Andres... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2019 Category: Pharmaceuticals Source Type: news
Many elderly patients with metastatic renal cell carcinoma benefit from targeted therapies
(University of Pennsylvania School of Medicine) Many elderly patients with metastatic renal cell carcinoma (RCC) -- who are often underrepresented in clinical trials to treat the kidney cancer -- are seeing overall survival benefits from treatment with targeted therapies, according to a new study published in JAMA Network Open. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 20, 2019 Category: International Medicine & Public Health Source Type: news
Do Brain Metastases Rule Out Immunotherapy in RCC?
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Dr. Daniel George on the Treatment Landscape for RCC
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Daniel George, MD Source Type: news
Patient Outcomes for Atezolizumab vs Sunitinib in Renal Cell Carcinoma
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Carmena Trial: Should Nephrectomy Be Standard for Metastatic RCC?
In this randomized phase III trial, researchers compared cytoreductive nephrectomy vs sunitinib alone in patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Benefit of Pembrolizumab/Axitinib Combo in Intermediate/Poor-Risk RCC
Pembrolizumab plus axitinib significantly improved overall survival, progression-free survival, and response rate as first-line treatment compared with sunitinib in patients with metastatic renal cell carcinoma (RCC) with intermediate/poor risk disease and those with sarcomatoid features, according to results of the KEYNOTE-426 study (abstract 4500) presented at the 2019 American Society of Clinical Oncology (ASCO) (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Pazopanib Followed by Nivolumab Shows Real-World Benefit in Metastatic RCC
The study of sequential treatment of pazopanib followed by nivolumab in advanced or metastatic renal cell carcinoma looked at benefit-risk profile and survival. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Advanced Refractory RCC: TIVO-3 Results Presented for Tivozanib vs Sorafenib
Progression-free survival was compared for the VEGF TKI tivozanib vs sorafenib across multiple subgroups of refractory advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Effect of Pazopanib on Survival After Metastasectomy in Metastatic RCC
The study investigators evaluated the survival benefit of pazopanib in metastatic renal cell carcinoma patients with no evidence of disease after metastasectomy. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
